About MicuRx Pharmaceuticals
MicuRx Pharmaceuticals is a company based in Foster City (United States) founded in 2007 by Zhengyu Yuan and Mikhail F Gordeev. MicuRx Pharmaceuticals has raised $389.28 million across 10 funding rounds from investors including Korea Investment Holdings, CARB-X and Legend Capital. The company has 4 employees as of December 31, 2022. MicuRx Pharmaceuticals operates in a competitive market with competitors including Kriya Therapeutics, Paratek Pharma, Spero Therapeutics, DermBiont and Cempra, among others.
- Headquarter Foster City, United States
- Employees 4 as on 31 Dec, 2022
- Founders Zhengyu Yuan, Mikhail F Gordeev
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Micurx Pharmaceuticals
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$389.28 M (USD)
in 10 rounds
-
Latest Funding Round
$106.93 M (USD), Series E
Dec 23, 2020
-
Investors
Korea Investment Holdings
& 9 more
-
Employee Count
4
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of MicuRx Pharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of MicuRx Pharmaceuticals
MicuRx Pharmaceuticals has successfully raised a total of $389.28M across 10 strategic funding rounds. The most recent funding activity was a Series E round of $106.93 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in MicuRx Pharmaceuticals
MicuRx Pharmaceuticals has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Korea Investment Holdings, CARB-X and Legend Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture Capital firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Investment holding firm established in Seoul in 2003.
|
Locked | Locked | Locked | |
|
AI solutions are provided for industrial monitoring and efficiency.
|
Locked | Locked | Locked |
Investor details for MicuRx Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MicuRx Pharmaceuticals
Investment portfolio details for MicuRx Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - MicuRx Pharmaceuticals
Detailed financials for MicuRx Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Micurx Pharmaceuticals Comparisons
Peer comparison for MicuRx Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MicuRx Pharmaceuticals
MicuRx Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Paratek Pharma, Spero Therapeutics, DermBiont and Cempra, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Therapeutics for antimicrobial resistant infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Microbial therapeutics for skin diseases are developed.
|
|
| Locked | Locked | Locked |
Clinical-stage pharmaceutical company focused on developing antibacterials
|
|
| Locked | Locked | Locked |
Drugs for antibiotic-resistant infections and cancer are developed.
|
Detailed competitors of MicuRx Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Micurx Pharmaceuticals
Complete news archive for MicuRx Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MicuRx Pharmaceuticals
MicuRx Pharmaceuticals was founded in 2007.
MicuRx Pharmaceuticals is headquartered in Foster City, United States. It is registered at Foster City, California, United States.
Zhengyu Yuan is the current CEO of MicuRx Pharmaceuticals. They have also founded this company.
MicuRx Pharmaceuticals is a funded company, having raised a total of $389.28M across 10 funding rounds to date.
As of Dec 31, 2022, the latest employee count at MicuRx Pharmaceuticals is 4.
MicuRx Pharmaceuticals develops antibiotics against multidrug-resistant (MDR) superbug infections. It is involved in the development of a portfolio that comprises a pipeline of antimicrobial agents to treat gram-positive bacteria, gram-negative bacteria, and fungal infections. Products include MRX-I, an oxazolidinone antibiotic for treating methicillin-resistant staphylococcus aureus and vancomycin-resistant enterococci infections which is in phase 3 of the clinical trial; and MRX-II, an oxazolidinone antibiotic for treating hospital-acquired infections. Other candidates are MRX-4 and MRX-8 which are effective against gram-positive and gram-negative bacteria are in phase 2 and 1 of the clinical trial.
MicuRx Pharmaceuticals's top competitors include Spero Therapeutics, Vedanta Biosciences and Paratek Pharma.
MicuRx Pharmaceuticals has 10 investors. Key investors include Korea Investment Holdings, CARB-X, Legend Capital, Yingke Capital, and AI PRO.